CytoMed Therapeutics Ltd — Form SCHEDULE 13D/A
Filed October 13, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 15/100
What the filing says
Choo Chee Kong filed an amended Schedule 13D/A regarding beneficial ownership in CytoMed Therapeutics Ltd on October 13, 2026. The specific amendments, share counts, percentages, and counterparty details are not disclosed in the available filing header text; the actual substantive disclosure document content was not provided for review.
Why this rating
Schedule 13D/A amendments are routine ownership disclosures. Without access to amendment specifics (share counts, ownership %, changes made), cannot assess materiality. Company scale unknown; no financial data provided.
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.